ClinicalTrials.gg
RecruitingNCT05459597Updated Jul 15, 2022

Antiepileptic Drugs in Elderly Patients

An observational study in Seizure, Epileptic, sponsored by Wei Zhao. Recruiting at 1 site in China. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by Wei Zhao · Observational

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
65 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Seizures with a site in China — 14 open to participants now, 16 under way, 9 of them phase 3. Seizures · China.

Planned enrollment
6th of 13
500 · median 500
Started
2021
with 3 others
Observational
13 of 39
6 open now
Primary completion
2028-03
later than 13 of 15 live
Registered
30th of 39
by date

Among the 39 studies in Seizures with a site in China, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2021, is one of 13 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 30th registered.

Seizures

766 studies on the registry are indexed under Seizures; 133 are open to participants now.

Browse Seizures studies →

Open to participants now

14 of the 39 studies in Seizures with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 65 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Seizures with a site in China, or all of them as a file.
02

Study summary

The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.

03

Conditions studied

  • Seizure, Epileptic

Browse trials for

04

Who can participate

Ages eligible
65 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Elderly patients with epilepsy (≥65years).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥65 years old;
  2. Diagnosed with epilepsy;
  3. Using antiepileptic drugs for treatment;

Exclusion criteria

Exclusion Criteria:

  1. Patients who are expected to die within 48 hours;
  2. Patients with allergy to antiepileptic drugs;
  3. Patients receiving other drugs;
  4. Other factors that the researcher considers unsuitable for inclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Days
Patient registry
Yes

Groups and cohorts

  • Treatment

    The use of antiepileptic drugs depends on the clinical practice.

    Drug: antiepileptic drugs

Interventions

  • Drugantiepileptic drugs

    phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.

06

What researchers measure

Primary outcomes

  1. The peak plasma drug concentration of antiepileptic drugs.

    To detect the peak plasma drug concentration of antiepileptic drugs.

    Time frame: at (0-4) h after oral administration

  2. The random plasma drug concentration of antiepileptic drugs.

    To detect the random plasma drug concentration of antiepileptic drugs.

    Time frame: at (4-10) h after oral administration

  3. The trough plasma drug concentration of antiepileptic drugs.

    To detect the trough plasma drug concentration of antiepileptic drugs.

    Time frame: at (1-2) h before the next administration

Secondary outcomes

  1. The incidence of adverse drug reaction

    Time frame: Through study completion, an average of 14 days

  2. The frequency of seizures

    Time frame: Through study completion, an average of 14 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Mar 2028, 86 months after the start.

Of 53 non-industry observational studies under Seizures, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 18. This study's planned 86 months is above that.

Counting every sponsor, half of 80 studies reached it within 37 months; a quarter within 18 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2022
First posted
Jul 15, 2022
StartActual
Jan 1, 2021
Primary completionEst.
Mar 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Jul 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05459597
Lead sponsor
Wei Zhao
Collaborators
Qianfoshan Hospital, The Second Hospital of Shandong University, The Affiliated Hospital of Qingdao University
Responsible party
Wei Zhao (Head of department of clinical pharmacy and pharmacology, Shandong University) — Sponsor-investigator
First posted
Jul 15, 2022
Start date
Jan 1, 2021
Primary completion
Mar 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 15, 2022

Study contacts

Wei Zhao
Contact
zhao4wei2@hotmail.com
86053188383308
Wei Zhao
study chair · Qianfoshan Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion